Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Nov 19, 2020

Ocuphire Pharma Announces Expansion of Global Patents for Nyxol® and $1.7 Million NIH Grants for APX3330 Program

Nov 16, 2020

Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program

Nov 12, 2020

Ocuphire to Participate in Upcoming Virtual HCW Conference in November

Nov 10, 2020

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Ocuphire Pharma Inc.

Nov 9, 2020

Industry Veteran Susan Benton Joins the Ocuphire Pharma Board of Directors

Nov 6, 2020

Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP

Nov 5, 2020

Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma

Nov 5, 2020

Ocuphire Pharma to Host Key Opinion Leader Event on Nyxol® and APX3330

Nov 3, 2020

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma

Nov 2, 2020